Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Cytokinetics Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $54.44, while Cytokinetics Inc trades at $84.55 (market cap $11.52B). The key difference: Cytokinetics Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | CYTK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.52 | $87.26 |
52-Week Low | $29.80 | $33.23 |
Market Cap | — | $11.52B |
Enterprise Value | — | $11.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
Cytokinetics (CYTK) trades at $84.87, down 1.39% today, with a bullish technical signal from moving averages and strong analyst support. The company's recent FDA approval of Myqorzo and European launch drive optimism, though financials show significant losses with a net income margin of -784.02% and negative cash flow from operations of -$510.01 million in 2025. Revenue growth is projected from $88 million to $106 million in 2026, but profitability remains a challenge.
The outlook hinges on Myqorzo's commercial success, with a consensus price target of $110.40 implying 30% upside. Risks include high cash burn, competitive pressures, and reliance on drug adoption. Institutional sentiment is overwhelmingly bullish, but investors must weigh the growth potential against persistent financial losses and execution risks in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
